14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $23.68 $29.88 Thursday, 2nd May 2024 BBIO stock ended at $27.74. This is 2.63% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 4.81% from a day low at $26.59 to a day high of $27.87.
90 days $23.68 $41.04
52 weeks $12.75 $44.32

Historical Bridgebio Pharma Inc. prices

Date Open High Low Close Volume
May 02, 2024 $27.60 $27.87 $26.59 $27.74 1 165 996
May 01, 2024 $25.85 $28.20 $25.84 $27.03 2 248 133
Apr 30, 2024 $25.22 $26.05 $24.95 $25.62 1 405 618
Apr 29, 2024 $25.12 $25.62 $25.01 $25.47 1 055 728
Apr 26, 2024 $24.48 $24.99 $24.32 $24.88 1 017 617
Apr 25, 2024 $24.42 $24.51 $23.68 $24.33 1 698 058
Apr 24, 2024 $25.37 $25.78 $24.44 $25.03 1 461 853
Apr 23, 2024 $25.08 $26.25 $25.08 $25.46 1 097 090
Apr 22, 2024 $24.99 $25.52 $24.14 $25.07 2 098 174
Apr 19, 2024 $24.88 $25.36 $24.27 $24.74 1 969 692
Apr 18, 2024 $24.85 $25.52 $24.78 $24.95 1 622 617
Apr 17, 2024 $25.54 $25.66 $24.80 $24.98 1 665 015
Apr 16, 2024 $25.39 $25.91 $25.20 $25.24 982 901
Apr 15, 2024 $26.68 $26.70 $25.70 $25.77 1 819 443
Apr 12, 2024 $27.92 $28.13 $26.37 $26.83 1 885 869
Apr 11, 2024 $27.70 $28.76 $26.86 $28.36 1 524 707
Apr 10, 2024 $27.29 $27.51 $26.73 $27.33 1 593 436
Apr 09, 2024 $28.27 $28.65 $27.91 $28.43 952 984
Apr 08, 2024 $28.39 $28.73 $27.87 $28.27 936 707
Apr 05, 2024 $27.90 $28.77 $27.73 $28.10 1 136 942
Apr 04, 2024 $29.47 $29.65 $28.11 $28.15 1 412 689
Apr 03, 2024 $29.01 $29.33 $28.28 $29.23 1 605 546
Apr 02, 2024 $29.88 $29.88 $28.60 $28.80 1 783 580
Apr 01, 2024 $30.99 $31.00 $29.66 $29.98 909 950
Mar 28, 2024 $30.78 $31.22 $30.37 $30.92 1 797 915
Click to get the best stock tips daily for free!

About Bridgebio Pharma Inc.

Bridgebio Pharma. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car... BBIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT